Exploring the Neurological Biomarkers Market Dynamics

Neurological biomarkers market size was valued at $5.4 billion in 2021, and is estimated to reach $18.9 billion by 2031, growing at a CAGR of 13.6% from 2022 to 2031. Ever-increasing rise in the incidence of Alzheimer’s and Parkinson’s is anticipated to contribute toward the robust growth of neurological biomarkers among these two applications. In addition, surge in adoption of neurological biomarkers in drug development and validation has increased over the years to improve the accuracy of clinical trials. Further, rise in transition toward personalized medicine is expected to offer profitable opportunities for the expansion of neurological biomarkers applied across Alzheimer’s and Parkinson’s. 

KEY BENEFITS FOR STAKEHOLDERS 

• The study provides an in-depth analysis of the neurological biomarkers market forecast, future estimations and neurological biomarkers market trends to elucidate the imminent investment pockets. 
• It presents a quantitative analysis of the market from 2021 to 2031 to enable stakeholders to capitalize on the prevailing neurological biomarkers market opportunity. 
• Extensive analysis of the market based on procedures and services assists to understand the trends in the neurological biomarkers industry. 
• Key players and their strategies are thoroughly analyzed to understand the competitive outlook of the neurological biomarkers industry. 

Market Size By 2031: 

• USD 18.9 billion 

Growth Rate: 

• CAGR of 13.6% 

Forecast period: 

• 2021 - 2031

By Type: 

• Genomic 
• Proteomic 
• Metabolomic 
• Others 

By Application: 

• Parkinson's Disease 
• Alzheimer's Disease 
• Multiple Sclerosis 

By Region: 

• North America  (U.S., Canada) 
• Europe  (Germany, France, UK, Rest Of Europe) 
• Asia-Pacific  (Japan, China, India, Rest Of Asia-Pacific) 
• LAMEA  (Brazil, Saudi Arabia, Rest Of LAMEA) 

𝐋𝐢𝐬𝐭 𝐨𝐟 𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬 : 

• Bio-Rad Laboratories, Inc. 
• Quanterix 
• merck kgaa 
• darmstadt 
• germany 
• bioMérieux 
• F. HOFFMANN-LA ROCHE LTD. 
• MYRIAD RBM (MYRIAD GENETICS, INC.) 
• PERKINELMER INC. 
• Thermo Fisher Scientific, Inc. 
• Neurobio, shimadzu corporation 

𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐒𝐚𝐦𝐩𝐥𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 https://www.alliedmarketresearch.com/request-sample/3555 

The neurological biomarkers market can be segmented in various ways based on different factors. Here are some common segmentation approaches for the neurological biomarkers market: 

Biomarker Type: 

a. Genomic Biomarkers: This segment includes biomarkers derived from genes and their expression patterns, such as single nucleotide polymorphisms (SNPs) and gene expression profiles. 

b. Proteomic Biomarkers: This segment includes biomarkers derived from proteins, such as protein expression levels, protein modifications, and protein-protein interactions. 

c. Imaging Biomarkers: This segment includes biomarkers obtained through various imaging techniques, such as magnetic resonance imaging (MRI), positron emission tomography (PET), and computed tomography (CT) scans. 

d. Metabolomic Biomarkers: This segment includes biomarkers derived from metabolites, such as small molecules and metabolic pathways. 

e. Others: This segment may include other types of biomarkers, such as epigenetic biomarkers or microRNA biomarkers. 

Disease Type: 

a. Alzheimer's Disease: This segment focuses on biomarkers associated with Alzheimer's disease, such as amyloid beta and tau proteins. 

b. Parkinson's Disease: This segment focuses on biomarkers associated with Parkinson's disease, such as alpha-synuclein and dopamine levels. 

c. Multiple Sclerosis: This segment focuses on biomarkers associated with multiple sclerosis, such as myelin basic protein and neurofilament light chain. 

d. Stroke: This segment focuses on biomarkers associated with stroke, such as brain-derived neurotrophic factor (BDNF) and glial fibrillary acidic protein (GFAP). 

e. Other Neurological Disorders: This segment may include biomarkers associated with other neurological disorders, such as epilepsy, Huntington's disease, and traumatic brain injury. 

End User: 

a. Hospitals and Clinics: This segment includes biomarker testing conducted in hospitals and clinics by healthcare professionals. 

b. Research Institutes and Academic Centers: This segment focuses on biomarker research conducted in academic and research settings. 

c. Diagnostic Laboratories: This segment includes biomarker testing conducted in specialized diagnostic laboratories. 

d. Pharmaceutical and Biotechnology Companies: This segment focuses on biomarker discovery and development carried out by pharmaceutical and biotech companies. 

Region: 

a. North America: This segment includes the United States and Canada. 

b. Europe: This segment includes countries in Europe, such as the United Kingdom, Germany, France, and Italy. 

c. Asia-Pacific: This segment includes countries in the Asia-Pacific region, such as China, Japan, India, and Australia. 

d. Latin America: This segment includes countries in Latin America, such as Brazil and Mexico. 

e. Middle East and Africa: This segment includes countries in the Middle East and Africa region. 

𝐁𝐮𝐲 𝐍𝐨𝐰: https://www.alliedmarketresearch.com/checkout-final/9f0e3bf3e66f160fbacb254909054633  

𝐀𝐕𝐄𝐍𝐔𝐄- 𝐀 𝐒𝐮𝐛𝐬𝐜𝐫𝐢𝐩𝐭𝐢𝐨𝐧-𝐁𝐚𝐬𝐞𝐝 𝐋𝐢𝐛𝐫𝐚𝐫𝐲 (𝐏𝐫𝐞𝐦𝐢𝐮𝐦 𝐨𝐧-𝐝𝐞𝐦𝐚𝐧𝐝, 𝐬𝐮𝐛𝐬𝐜𝐫𝐢𝐩𝐭𝐢𝐨𝐧-𝐛𝐚𝐬𝐞𝐝 𝐩𝐫𝐢𝐜𝐢𝐧𝐠 𝐦𝐨𝐝𝐞𝐥) 𝐎𝐟𝐟𝐞𝐫𝐞𝐝 𝐛𝐲 𝐀𝐥𝐥𝐢𝐞𝐝 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡: 

AMR introduces its online premium subscription-based library Avenue, designed specifically to offer cost-effective, one-stop solution for enterprises, investors, and universities. With Avenue, subscribers can avail an entire repository of reports on more than 2,000 niche industries and more than 12,000 company profiles. Moreover, users can get an online access to quantitative and qualitative data in PDF and Excel formats along with analyst support, customization, and updated versions of reports. 

Procure Complete Report (220+ Pages PDF with Insights, Charts, Tables, and Figures) @ https://www.alliedmarketresearch.com/purchase-enquiry/3555  

𝐀𝐛𝐨𝐮𝐭 𝐀𝐥𝐥𝐢𝐞𝐝 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡: 

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain. 

Contact Us: 

David Correa 

Portland, OR, United States 

USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022,  

UK: +44-845-528-1300 

Hong Kong: +852-301-84916 

India (Pune): +91-20-66346060 

Fax: +1(855)550-5975 

[email protected]  

Web: https://www.alliedmarketresearch.com